<DOC>
	<DOC>NCT02442817</DOC>
	<brief_summary>The purpose of the present study is to gather pilot data on the effects of linagliptin on the concentration of the long and short forms of SDF1-α (stromal cell-derived factor alpha) in humans, and to demonstrate the feasibility of such a study in patients with psychosis in our setting.</brief_summary>
	<brief_title>Linagliptin and Mesenchymal Stem Cells: A Pilot Study</brief_title>
	<detailed_description>This study is a 13-week, open-label study of 8 participants with schizophrenia and minimal thought disorder; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic treatment. The principal outcome measures will be the concentrations of the long and short forms of SDF1-α (stromal cell-derived factor alpha) in blood.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Meets DSM (Diagnostic and Statistical Manual) criteria for schizophrenia. Considered clinically stable, and on the same dose of antipsychotic for two weeks. A score no greater than 3 on the PANSS (Positive and Negative Syndrome Scale) Conceptual Disorganization item. Not taking any medications for diabetes, or any antiinflammatories other than occasional aspirin or acetaminophen. Not taking Clozapine. Age 1845 years. Can be available for regular morning appointments from 8:00 am to 10:00 am, preferably on Tuesdays, Wednesdays and Thursdays. Does not meet DSM criteria for substance abuse or dependence. No serious current general medical condition, such as cancer, history of stroke or myocardial infarction, tuberculosis, HIV/AIDS, hemophilia, etc.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>DPP-4 Inhibitor</keyword>
	<keyword>Linagliptin</keyword>
	<keyword>SDF1-α</keyword>
</DOC>